A germline deletion of p14ARF but not CDKN2A in a melanoma-neural system tumour syndrome family

被引:203
作者
Randerson-Moor, JA
Harland, M
Williams, S
Cuthbert-Heavens, D
Sheridan, E
Aveyard, J
Sibley, K
Whitaker, L
Knowles, M
Bishop, JN
Bishop, DT
机构
[1] St James Univ Hosp, Imperial Canc Res Fund, Ctr Clin, Genet Epidemiol Div, Leeds LS9 7TF, W Yorkshire, England
[2] St James Univ Hosp, Imperial Canc Res Fund, Ctr Clin, Genet Mol Lab, Leeds LS9 7TF, W Yorkshire, England
[3] St James Univ Hosp, Imperial Canc Res Fund, Mutat Detect Facil, Leeds LS9 7TF, W Yorkshire, England
[4] St James Univ Hosp, Imperial Canc Res Fund, Ctr Clin, Canc Med Unit, Leeds LS9 7TF, W Yorkshire, England
关键词
D O I
10.1093/hmg/10.1.55
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The melanoma-astrocytoma syndrome is characterized by a dual predisposition to melanoma and neural system tumours, commonly astrocytoma. Germline deletions of the region on 9p21 containing the CDKN2A and CDKN2B genes and CDKN2A exon 1 beta have been reported in kindreds, implicating contiguous tumour suppressor gene deletion as a cause of this syndrome. We describe a family characterized by multiple melanoma and neural cell tumours segregating with a germline deletion of the p14(ARF)-specific exon 1 beta of the CDKN2A gene. This deletion does not affect the coding or minimal promoter sequences of either the CDKN2A or CDKN2B genes. Our results are consistent with either: (i) loss of p14(ARF) function being the critical abnormality associated with this syndrome, rather than contiguous loss of both the CDKN2A and CDKN2B genes as suggested previously; or (ii) disruption of expression of p16 by mechanisms as yet unknown.
引用
收藏
页码:55 / 62
页数:8
相关论文
共 44 条
[1]  
AZIZI E, 1995, CANCER, V76, P1571, DOI 10.1002/1097-0142(19951101)76:9<1571::AID-CNCR2820760912>3.0.CO
[2]  
2-6
[3]  
Bahuau M, 1998, CANCER RES, V58, P2298
[4]  
Bahuau M, 1997, ANN GENET-PARIS, V40, P78
[5]   FREQUENCY OF HOMOZYGOUS DELETION AT P16/CDKN2 IN PRIMARY HUMAN TUMORS [J].
CAIRNS, P ;
POLASCIK, TJ ;
EBY, Y ;
TOKINO, K ;
CALIFANO, J ;
MERLO, A ;
MAO, L ;
HERATH, J ;
JENKINS, R ;
WESTRA, W ;
RUTTER, JL ;
BUCKLER, A ;
GABRIELSON, E ;
TOCKMAN, M ;
CHO, KR ;
HEDRICK, L ;
BOVA, GS ;
ISAACS, W ;
KOCH, W ;
SCHWAB, D ;
SIDRANSKY, D .
NATURE GENETICS, 1995, 11 (02) :210-212
[6]   p16INK4A and p19ARF act in overlapping pathways in cellular immortalization [J].
Carnero, A ;
Hudson, JD ;
Price, CM ;
Beach, DH .
NATURE CELL BIOLOGY, 2000, 2 (03) :148-155
[7]  
Dracopoli NC, 1996, CANCER SURV, V26, P115
[8]   CDKN2a/p16INK4a mutations and lack of 0p19ARF involvement in familial melanoma kindreds [J].
Fargnoli, MC ;
Chimenti, S ;
Keller, G ;
Soyer, HP ;
Dal Pozzo, V ;
Höfler, H ;
Peris, K .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1998, 111 (06) :1202-1206
[9]   Prevalence of germ-line mutations in p16, p19ARF, and CDK4 in familial melanoma: Analysis of a clinic-based population [J].
FitzGerald, MG ;
Harkin, DP ;
SilvaArrieta, S ;
MacDonald, DJ ;
Lucchina, LC ;
Unsal, H ;
ONeill, E ;
Koh, J ;
Finkelstein, DM ;
Isselbacher, KJ ;
Sober, AJ ;
Haber, DA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (16) :8541-8545
[10]   Analysis of the CDKN2A, CDKN2B and CDK4 genes in 48 Australian melanoma kindreds [J].
Flores, JF ;
Pollock, PM ;
Walker, GJ ;
Glendening, JM ;
Lin, AHT ;
Palmer, JM ;
Walters, MK ;
Hayward, NK ;
Fountain, JW .
ONCOGENE, 1997, 15 (24) :2999-3005